The JMP Securities Hematology and Oncology Summit
For Fiscal Year Ending Jun 30, 2022
Stay informed and receive updates directly to your inbox.Sign up today
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.